nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2023-1-119-122nnp-1965Research ArticleDISCUSSIONДИСКУССИЯComments on the article “Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy”Комментарии к статье «Консенсусное мнение по ведению пациентов с заболеваниями спектра оптиконевромиелита: вопросы терминологии и терапии»https://orcid.org/0000-0002-2975-4151БойкоА. Н.BoykoA. N.

Алексей Николаевич Бойко

117997, Москва, ул. Островитянова, 1117997, Москва, ул. Островитянова, 1, стр. 10

Alexey Nikolaevich Boyko

117997, Moscow, Ostrovityanova St., 1117997, Moscow, Ostrovityanova St.,1, Build. 10

boykoan13@gmail.comКафедра неврологии и нейрохирургии ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБАРоссияDepartment of Neurology, Neurosurgery and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Institute of Clinical Neurology, Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of RussiaRussian Federation202319022023151119122Copyright © Boyko A.N., 20232023Бойко А.Н.Boyko A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1965

Comments were provided on the article on the management of patients with neuromyelitis optica spectrum diseases (NMOSD), published in the journal "Neurology, Neuropsychiatry, Psychosomatics" No. 6 for 2022. The main comments relate to the management of patients with NMOSD who do not have antibodies to aquaporin-4 (AQP4-Ab), and methods for detecting these antibodies.

Приводятся комментарии к статье, посвященной вопросу ведения пациентов с заболеваниями спектра оптиконевромиелита (ЗСОМН), опубликованной в №6 журнала «Неврология, нейропсихиатрия, психосоматика» за 2022 г. Основные комментарии касаются вопросов ведения пациентов с ЗСОНМ, не имеющих антител к аквапорину-4, и методов выявления этих антител.

заболевания спектра оптиконевромиелитаантитела к аквапорину-4ведение пациентовneuromyelitis optica spectrum diseasesantibodies to aquaporin-4management of patientsReferencesКраснов ВС, Бахтиярова КЗ, Евдошенко ЕП и др. Консенсусное мнение по ведению пациентов с заболеваниями спектра оптиконевромиелита: вопросы терминологии и терапии. Неврология, нейропсихиатрия, психосоматика. 2022;14(6):139-48. doi:10.14412/2074-2711-2022-6-139-148Krasnov VS, Bakhtiyarova KZ, Evdoshenko EP, et al. Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):139-48. doi:10.14412/2074-2711-2022-6-139-148 (In Russ.).Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-14. doi:10.1212/WNL.53.5.1107Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-14. doi:10.1212/WNL.53.5.1107Журавлёв МН, Сиверцева СА, Молокова МЮ и др. Оптикомиелит или болезнь Девика – патогенез, клиника, диагностика и опыт лечения с использованием бетаферона и митоксантрона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007;107(Спец. выпуск «Рассеянный склероз» 4):106-12.Zhuravlev MN, Sivertseva SA, Molokova MYu, et al. Opticomyelitis or Devik's disease – pathogenesis, clinic, diagnosis and treatment experience using betaferon and mitoxantrone. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2007;107(SI.4):106-12 (In Russ.).Kira J. Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann N Y Acad Sci. 2008 Oct;1142:58-71. doi:10.1196/annals.1444.002Kira J. Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann N Y Acad Sci. 2008 Oct;1142:58-71. doi:10.1196/annals.1444.002Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-15. doi:10.1016/S1474-4422(07)70216-8Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-15. doi:10.1016/S1474-4422(07)70216-8Wingerchuk DM, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. doi:10.1212/WNL.0000000000001729Wingerchuk DM, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. doi:10.1212/WNL.0000000000001729Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi:10.3389/fneur.2020.00501Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi:10.3389/fneur.2020.00501Шерман МА, Бойко АН. Эпидемиология заболеваний спектра оптиконевромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(7-2):5-12. doi:10.17116/jnevro20211210725Sherman MA, Boyko AN. Epidemiology of diseases of the spectrum of opticoneuromyelitis. Zhurnal nevrologii i psikhiatriiimeni S.S. Korsakova. 2021;121(7-2):5-12. doi:10.17116/jnevro20211210725 (In Russ.).Стародубов ВИ, Зеленова ОВ, Абрамов СИ и др. Первое обсервационное эпидемиологическое исследование по определению заболеваемости и распространенности заболеваний спектра оптиконевромиелита (оптиконевромиелит, болезнь Девика) на территории Российской Федерации. Современные проблемы здравоохранения и медицинской статистики. 2021;(1):130-41. doi:10.24411/2312-2935-2021-00007Starodubov VI, Zelenova OV, Abramov SI, et al. The first observational epidemiological study to determine the incidence and prevalence of diseases of the spectrum of opticoneuromyelitis (opticoneuromyelitis, Devik's disease) on the territory of the Russian Federation. Sovremennye problem zdravookhraneniya i meditsinskoi statistiki = Current Problems of Health Care and Medical Statistics. 2021;(1):130-41. doi:10.24411/2312-2935-2021-00007 (In Russ.).Хайбуллин ТН, Кириллова ЕВ, Бикбаев РМ, Бойко АН. Клинико-эпидемиологические характеристики рассеянного склероза и оптиконейромиелита в Центральной Азии. Журнал неврологии и психиатрии им. С.С.Корсакова. 2019;119(2-2):12-7. doi:10.17116/jnevro20191192212Khaibullin TN, Kirillova EV, Bikbaev RM, Boyko AN. Clinical-epidemiological characteristics of multiple sclerosis and neuroopticomyelitis in the Central Asia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(2-2):12-7. doi:10.17116/jnevro20191192212 (In Russ.).Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-95. doi:10.1111/joim.12395Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-95. doi:10.1111/joim.12395Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-12. doi:10.1016/S0140-6736(04)17551-XLennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-12. doi:10.1016/S0140-6736(04)17551-XPapadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535-44. doi:10.1016/S1474-4422(12)70133-3Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535-44. doi:10.1016/S1474-4422(12)70133-3Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017;92(4):663-79. doi:10.1016/j.mayocp.2016.12.014Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017;92(4):663-79. doi:10.1016/j.mayocp.2016.12.014Белова АН, Бойко АН, Белова ЕМ. Диагностические критерии оптикомиелитассоциированных расстройств. Журнал неврологии и психиатрии им. С.С.Корсакова. 2016;116 (2-2):32-40. doi:10.17116/jnevro20161162232-40Belova AN, Boyko AN, Belova EM. Diagnostic criteria of opticomyelitis-associated disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(2-2):32-40. doi:10.17116/jnevro20161162232-40 (In Russ.).Симанив ТО, Васильев АВ, Аскарова ЛШ, Захарова МН. Оптиконейромиелит и заболевания спектра оптиконейромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(10-2):35-48. doi:10/17116/jnevro20191191035Simaniv TO, Vasiliev AV, Askarova LSh, Zakharova MN. Neuromyelitis optica and neuromyelitis optica spectrum disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(10-2):35-48. doi:10/17116/jnevro20191191035 (In Russ.).Гусев ЕИ, Бойко АН. Рассеянный склероз. Научно-практическое руководство. В 2-х т. Москва: РООИ «Здоровье человека»; 2020. Т. 1. 608 с.; Т. 2. 572 с.Gusev EI, Boyko AN. Rasseyannyy skleroz. Nauchno-prakticheskoye rukovodstvo [Multiple sclerosis. Scientific and practical guide]. In 2 volumes. Moscow: ROOI “Human Health”; 2020. Vol. 1. 608 p.; Vol. 2. 572 p. (In Russ.).Lana-Peixoto MA, Talim N. Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomedicines. 2019;7:42. doi:10.3390/biomedicines7020042Lana-Peixoto MA, Talim N. Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomedicines. 2019;7:42. doi:10.3390/biomedicines7020042Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroinflam. 2018;15:134. doi:10.1186/s12974-018-1144-2Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroinflam. 2018;15:134. doi:10.1186/s12974-018-1144-2Carnero Contentti E, Marrodan M, Correale J. Emerging drugs for the treatment of adultMOG-IgG-associateddiseases. Expert Opin Emerg Drugs. 2021;26(2):75-8. doi:10.1080/14728214.2021.1919082Carnero Contentti E, Marrodan M, Correale J. Emerging drugs for the treatment of adultMOG-IgG-associateddiseases. Expert Opin Emerg Drugs. 2021;26(2):75-8. doi:10.1080/14728214.2021.1919082Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6:85. doi:10.1038/s41572-020-0214-9Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6:85. doi:10.1038/s41572-020-0214-9Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflam. 2021;18(1):208. doi:10.1186/s12974-021-02249-1Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflam. 2021;18(1):208. doi:10.1186/s12974-021-02249-1Velasco M, Zarco LA, Agudelo-Arrieta M, et al. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature. Mult Scler Relat Disord. 2021;50:102869. doi:10.1016/j.msard.2021.102869Velasco M, Zarco LA, Agudelo-Arrieta M, et al. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature. Mult Scler Relat Disord. 2021;50:102869. doi:10.1016/j.msard.2021.102869Popiel M, Psujek M, Bartosik-Psujek H. Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate. Mult Scler Relat Disord. 2018;26:204-6. doi:10.1016/j.msard.2018.09.011Popiel M, Psujek M, Bartosik-Psujek H. Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate. Mult Scler Relat Disord. 2018;26:204-6. doi:10.1016/j.msard.2018.09.011Lee DH, Laemmer AB, Waschbisch A, et al. Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report. J Med Case Rep. 2014;8:155. doi:10.1186/1752-1947-8-155Lee DH, Laemmer AB, Waschbisch A, et al. Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report. J Med Case Rep. 2014;8:155. doi:10.1186/1752-1947-8-155Yamout BI, Beaini S, Zeineddine MM, Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Mult Scler. 2017;23(9):1297-300. doi:10.1177/1352458517694086Yamout BI, Beaini S, Zeineddine MM, Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Mult Scler. 2017;23(9):1297-300. doi:10.1177/1352458517694086Kira JJ. Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? Mult Scler. 2017;23(9):1300-2. doi:10.1177/1352458517703803Kira JJ. Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? Mult Scler. 2017;23(9):1300-2. doi:10.1177/1352458517703803Краснов ВС, Тотолян НА, Назаров ВД и др. Актуальные вопросы диагностики заболеваний спектра оптиконейромиелита при определении антител к аквапорину-4 в сыворотке крови. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(7-2):24-31. doi:10.17116/jnevro202012007224Krasnov VS, Totolyan NA, Nazarov VD, et al. Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2020;120(7-2):24-31. doi:10.17116/jnevro202012007224 (In Russ.).Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614-25. doi:10.1056/NEJMoa1900866Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614-25. doi:10.1056/NEJMoa1900866Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114-24. doi:10.1056/NEJMoa1901747Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114-24. doi:10.1056/NEJMoa1901747Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-12. doi:10.1016/S1474-4422(20)30078-8Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-12. doi:10.1016/S1474-4422(20)30078-8Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78:665-71. doi:10.1212/WNL.0b013e318248dec1Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78:665-71. doi:10.1212/WNL.0b013e318248dec1Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23(6):661-83. doi:10.1111/bpa.12084Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23(6):661-83. doi:10.1111/bpa.12084Sato DK, Nakashina I, Takahashi T, et al. Aquaporine-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology. 2013;80:2210-6. doi:10.1212/WNL.0b013e318296ea08Sato DK, Nakashina I, Takahashi T, et al. Aquaporine-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology. 2013;80:2210-6. doi:10.1212/WNL.0b013e318296ea08Waters P, Pittock SJ, Bennett JL, et al. Evaluation of aquaporine-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290-303. doi:10.1111/cen3.12107Waters P, Pittock SJ, Bennett JL, et al. Evaluation of aquaporine-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290-303. doi:10.1111/cen3.12107Pittock SJ, Lennon VA, Bashi N, et al. Seroprevalence of aquaporine-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol. 2014;71(11):1433-6. doi:10.1001/jamaneurol.2014.1581Pittock SJ, Lennon VA, Bashi N, et al. Seroprevalence of aquaporine-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol. 2014;71(11):1433-6. doi:10.1001/jamaneurol.2014.1581Boyko A, Fernandez O, Alifirova V, et al. Survey of diagnostic and treatment practices for multiple sclerosis in Russian Federation in comparison to European data. Mult Scler Relat Disord. 2021 Oct;55:103201. doi:10.1016/j.msard.2021.103201. Epub 2021 Aug 8.Boyko A, Fernandez O, Alifirova V, et al. Survey of diagnostic and treatment practices for multiple sclerosis in Russian Federation in comparison to European data. Mult Scler Relat Disord. 2021 Oct;55:103201. doi:10.1016/j.msard.2021.103201. Epub 2021 Aug 8.

The authors declare that there are no conflicts of interest present.